Pharmalot... Pharmalittle... Good Morning

And so, the middle of the week has arrived. There are, of course, two ways to view this: Is the glass half full or half empty? While you ponder, please join us for a delicious cup of stimulation as we attack our stack of reading matter and attempt to catch up with interesting people. Meanwhile, here are a few items to help you on your way. We hope you have a grand day and do stay in touch. Manning and Snowden aside, we accept classified documents... Budget Cuts Force US To Cut Back Health Care Fraud Probes (The Washington Post) Cubist Buys Trius Therapeutics And Optimer Pharma For $1.6 Billion (Bloomberg News) AstraZeneca To Spend Up To $815M For Rights To FibroGen Anemia Pill (Reuters) Merck Strikes Deal With Bionomics For Chronic Pain Compound (Brisbane Times) Sanofi Allergy Drug Is Safe For Non-Prescription Use: FDA Reviewers (Reuters) European Heart Guidelines Based On Bad Research May Have Caused Many Deaths (CardioBrief) EDITOR'S NOTE: Please check this post for additional stories during the day Read more
Source: Pharmalot - Category: Pharma Commentators Authors: Source Type: blogs